*最早预计在本年底供应疫苗
Vaccine supply, at the earliest, is expected by the end of this year*公共卫生部旨在采购足量的疫苗，保证每个有资格的人都能够接种
MoPH aims to procure enough doses to vaccinate everyone eligible
一位高层官员在周日的声明中说道，公共卫生部同一些国际制药公司谈判进入最后阶段，在新冠疫苗全球发行使用之际并立即采购。
The Ministry of Public Health (MoPH) is in advanced negotiations with a number of international pharmaceutical companies to procure a Covid-19 vaccine as soon as it is released for global use, a top official confirmed Sunday in statement.
哈马德医疗集团传染病主任兼国家卫生战略集团主席Abdullatif博士解释道“目的是采购足量的疫苗，确保在卡塔尔每个满足条件的人尽快接种疫苗。” "The aim is to procure a sufficient quantity of vaccines to ensure everyone who is eligible for the vaccine in Qatar is able to receive one as soon as possible," explained Dr Abdullatif al-Khal, chair of the National Health Strategic Group on Covid-19 and Head of Infectious Diseases at Hamad Medical Corporation.
Al-Khal博士说道“我很高兴宣布，公共卫生部已经同Pfizer及BioNTech公司签署协议，向卡塔尔提供该公司用于预防SARS-CoV2的基于信使RNA的BNT162候选疫苗。该疫苗目前还在临床试验，只有当获得所有必要的相关监管部门的批准后，才会发行次疫苗。如果临床成功并获得了所有必要的监管部门的批准，预计可在2020年底到2021年期间供应疫苗。” “I am delighted to announce that the Ministry of Public Health has already signed an agreement with Pfizer and BioNTech to supply Qatar with their BNT162 mRNA-based candidate vaccine against SARS-CoV-2. The vaccine is still in the process of undergoing clinical trials and only once all necessary regulatory approvals have been given will the vaccine be distributed. Supply is planned for the end of 2020 to 2021, subject to clinical success and necessary regulatory approvals,” stated Dr al-Khal.
“我们同Pfizer和BioNTech公司的协议是卡塔尔应对全球疫情威胁的众多措施之一，当时在当前阶段，没有批准可用的疫苗，我想提醒大家，在获得疫苗以前，还需要继续遵守相关预防性措施，保证安全。” “Our agreement with Pfizer and BioNTech is one of the options to help address the threat of this global pandemic in Qatar but in the interim period while no approved vaccine is available I would like to remind people of the need to follow the preventive measures and stay safe until such a vaccine is available.”
Al-Khal博士回忆道，卡塔尔全方位的保护人民免于新冠的策略非常有效，最终控制了疫情，成为世界上死亡率最多的国家。 【 半岛华人注：目前卡塔尔确诊总数12.6万，感染率位居世界之首。死亡率低，很大一部分得益于卡塔尔人口组成中大多数为年轻的外籍劳工 ， 卡塔尔本身并没有采取什么积极措施，没有封城，没有大范围的消毒工作，目前基本是在执行全民免疫。 】
Dr al-Khal recalled that Qatar’s comprehensive strategy to protect its population from Covid-19 has been very effective and has resulted in controlling the pandemic and having one of the world’s lowest Covid-19 mortality rates.
他指出：“尽管我们成功地控制住了病毒扩张，但目前很清楚，正如世界上的其他国家一样，要同新冠病毒共存一段时间。” "Yet despite our success in controlling the spread of the virus it is clear that Qatar, like other countries around the world, will be living with Covid-19 for some time to come,” he pointed out.
“当前在执行的预防性措施有佩戴口罩、保持安全距离以及*会集**限制，这些措施是控制新冠病毒传播和保护人民的关键，只有在拥有疫苗后，我们才能恢复到正常生活”他强调到。 “The preventive measures currently in place, such as the wearing of masks, keeping a safe distance and limitations on gatherings, are key to controlling the spread of Covid-19 and protecting the population, but only when we have an effective vaccine will we be able to fully return towards normal life,” he stressed.
“还有另外一个问题，那就是目前我们正在逐渐进入季节性流感的高发期，今年要远比往年重要，人们应该去接种疫苗。那些很容易患有新冠重症的人群，比如年老者，慢性病患者，都极易感染流感。” “On a related note, as we approach the time of year when seasonal influenza reaches its peak, it is more important than ever this year that people receive the flu vaccine. Those population groups most vulnerable to severe symptoms from Covid-19, such as the elderly and people with chronic conditions, are also at greatest risk from the flu.
“在接下来的几天，公共卫生部将发起流感疫苗活动，向所有的公民和市民免费提供疫苗。首先给易感染且容易得流感并发症的人群接种疫苗，比如老年人，5岁以下的儿童，还有所有的慢性病患者。我督促所有人，特别是那些高危人群，在今年一定要接种疫苗。” "In the coming days the Ministry of Public Health will be launching its flu vaccination campaign, providing free flu vaccines for all citizens and residents. Priority will be given to vulnerable people at high risk of developing flu complications such as older people and children below five as well as patients with chronic diseases at any age. I urge everyone, especially those at most risk, to take the flu vaccine this year,” added Dr al-Khal.
在网络上搜寻的辉瑞研发会的最新消息：
9月15日辉瑞研发交流大会，公司披露了新冠疫苗BNT162最新研究进展。
1、截至9月14日，美国、巴西、阿根廷已经入组29012人；周六宣布目标入组人数已经从3万扩增到4.4万人，包含16-18岁少年、HIV、乙丙肝患者等，公司解释主要是看到了更多安全性数据，主动增加纳入人群，另外也不会影响完成时间。
预计早期数据下个月可提交审评。
2、安全性数据：目前未揭盲数据显示整体安全性良好，跟一期试验基本一致。数据涵盖约6000人，有些在试验中出现严重健康问题，经判定都和疫苗无关。
3、供应量：2020年预计可供应1亿支；2021年预计13亿支。
4、冷链及物流：公司预计冷链不会出现问题。超低温冰箱可储存6个月、干冰运输15天（零下80摄氏度）、2-8摄氏度冰箱储存5天；每瓶5人份剂量。
5、不同保护效力时常有待研究，对应后续不同接种策略——每年、数年加强或终身。
6、后续研发：新剂型不需要冷藏（有可能是冻干）、两针变为一针注射。
会议总结，Science will win.